251. Urea cycle disorder Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 54 / Drugs : 61 - (DrugBank : 15) / Drug target genes : 3 - Drug target pathways : 28
Urea cycle disorder and other diseases between which drug repositioning (DR) might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Score (Drug repositionability)
ID | Diseases (Sorted by score) | Score |
---|---|---|
251 | Urea cycle disorder | - |
300 | IgG4-related disease | 2.400 |
35 | Pemphigus | 2.352 |
271 | Ankylosing spondylitis | 2.305 |
78 | Hypopituitarism | 2.301 |
11 | Myasthenia gravis | 2.300 |
107 | Juvenile idiopathic arthritis | 2.293 |
298 | Hereditary pancreatitis | 2.292 |
3 | Spinal muscular atrophy | 2.292 |
113 | Muscular dystrophy | 2.288 |
222 | Primary nephrotic syndrome | 2.287 |
226 | Interstitial cystitis with Hunners ulcer | 2.285 |
70 | Spinal stenosis | 2.284 |
65 | Primary immunodeficiency | 2.275 |
299 | Cystic fibrosis | 2.273 |
86 | Pulmonary arterial hypertension | 2.272 |
51 | Scleroderma | 2.270 |
49 | Systemic lupus erythematosus | 2.270 |
97 | Ulcerative colitis | 2.266 |
96 | Crohn disease | 2.263 |
46 | Malignant rheumatoid arthritis | 2.262 |
6 | Parkinson disease | 2.262 |
13 | Multiple sclerosis/Neuromyelitis optica | 2.258 |
337 | Homocystinuria | 2.000 |
22 | Moyamoya disease | 1.071 |
225 | Congenital nephrogenic diabetes insipidus | 1.067 |
256 | Muscle glycogenosis | 1.065 |
210 | Single Ventricle | 1.062 |
231 | Alpha-1-antitrypsin deficiency | 1.057 |
158 | Tuberous sclerosis | 1.057 |
296 | Biliary atresia | 1.044 |
21 | Mitochondrial disease | 1.043 |
58 | Hypertrophic cardiomyopathy | 1.042 |
206 | Fragile X syndrome | 1.037 |
5 | Progressive supranuclear palsy | 1.031 |
28 | Systemic amyloidosis | 1.030 |
34 | Neurofibromatosis | 1.023 |
2 | Amyotrophic lateral sclerosis | 1.012 |
220 | Rapidly progressive glomerulonephritis | 1.000 |
30 | Distal myopathy | 1.000 |
245 | Propionic acidemia | 1.000 |